display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced RCC (mRCC) - 1st line (L1)
metastatic/advanced RCC (mRCC) - 1st line (L1)
pembrolizumab plus axitinib KEYNOTE-426

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons